Use of oral prednisolone | Bone-related conditions | Hypertension | Peptic ulcer | Severe Infectionsa | Herpes zoster | DM2 | Cataract | Glaucoma | CKD | Affective disorders | Cardiovascular events |
---|---|---|---|---|---|---|---|---|---|---|---|
No use (reference) | |||||||||||
Cases, n (%) | 4558 (51.2) | 4397 (54.0) | 416 (49.8) | 7642 (47.3) | 2056 (49.4) | 2571 (49.6) | 2582 (48.5) | 769 (52.4) | 4344 (49.5) | 2769 (55.8) | 2096 (52.2) |
Controls, n (%) | 19,038 (53.7) | 17,802 (54.9) | 1805 (54.2) | 36,039 (56.0) | 8875 (53.5) | 11,071 (53.4) | 10,641 (50.6) | 3048 (52.3) | 17,768 (51.1) | 12,016 (60.7) | 8827 (55.4) |
Current use (< 180 d before ID) | |||||||||||
Cases, n (%) | 846 (9.5) | 654 (8.0) | 80 (9.6) | 2227 (13.8) | 406 (9.8) | 596 (11.5) | 433 (8.1) | 119 (8.1) | 811 (9.2) | 434 (8.8) | 379 (9.4) |
Controls, n (%) | 2614 (7.4) | 2414 (7.4) | 225 (6.8) | 4489 (7.0) | 1307 (7.9) | 1617 (7.8) | 1612 (7.7) | 463 (7.9) | 2763 (8.0) | 1210 (6.1) | 1138 (7.1) |
OR crude (95% CI) | 1.36 (1.26–1.47) | 1.10 (1.01–1.20) | 1.57 (1.23–2.01) | 2.38 (2.26–2.50) | 1.36 (1.22–1.52) | 1.60 (1.46–1.75) | 1.11 (1.00–1.23) | 1.02 (0.84–1.24) | 1.21 (1.12–1.30) | 1.58 (1.42–1.75) | 1.41 (1.26–1.58) |
ORadjb (95% CI) | 1.27 (1.17–1.37) | 1.03 (0.94–1.12) | 1.47 (1.12–1.92) | 2.16 (2.05–2.27) | 1.32 (1.19–1.48) | 1.35 (1.22–1.49) | 1.03 (0.93–1.15) | 1.06 (0.87–1.29) | 1.14 (1.06–1.24) | 1.47 (1.32–1.63) | 1.33 (1.18–1.49) |
Recent use (180–365 d before ID) | |||||||||||
Cases, n (%) | 519 (5.8) | 405 (5.0) | 50 (6.0) | 1121 (6.9) | 267 (6.4) | 293 (5.7) | 310 (5.8) | 75 (5.1) | 478 (5.5) | 308 (6.2) | 212 (5.3) |
Controls, n (%) | 1858 (5.2) | 1608 (5.0) | 159 (4.8) | 3087 (4.8) | 889 (5.4) | 1036 (5.0) | 1102 (5.2) | 297 (5.1) | 1850 (5.3) | 871 (4.4) | 765 (4.8) |
OR crude (95% CI) | 1.18 (1.08–1.29) | 1.02 (0.92–1.13) | 1.36 (1.01–1.83) | 1.74 (1.63–1.86) | 1.32 (1.16–1.50) | 1.23 (1.09–1.39) | 1.17 (1.04–1.31) | 0.99 (0.75–1.26) | 1.06 (0.97–1.17) | 1.55 (1.38–1.75) | 1.18 (1.03–1.37) |
ORadjb (95% CI) | 1.12 (1.02–1.24) | 0.95 (0.85–1.05) | 1.19 (0.87–1.62) | 1.59 (1.49–1.70) | 1.29 (1.13–1.47) | 1.05 (0.92–1.19) | 1.12 (0.99–1.26) | 1.00 (0.79–1.28) | 1.00 (0.91–1.10) | 1.49 (1.32–1.69) | 1.11 (0.95–1.29) |
Past use (> 365 d before ID) | |||||||||||
Cases, n (%) | 2984 (33.5) | 2692 (33.0) | 289 (34.6) | 5170 (32.0 | 1434 (34.5) | 1729 (33.3) | 2002 (37.6) | 504 (34.4) | 3145 (35.8) | 1451 (29.2) | 1327 (33.1) |
Controls, n (%) | 11,935 (33.7) | 10,607 (32.7) | 1139 (34.2) | 20,701 (32.2) | 5534 (33.3) | 6991 (33.8) | 7664 (36.5) | 2024 (34.7) | 12,381 (35.6) | 5712 (28.8) | 5215 (32.7) |
OR crude (95% CI) | 1.05 (1.00–1.10) | 1.03 (0.98–1.08) | 1.11 (0.95–1.30) | 1.20 (1.16–1.25) | 1.13 (1.05–1.21) | 1.08 (1.01–1.15) | 1.08 (1.02–1.15) | 0.99 (0.88–1.11) | 1.04 (0.99–1.09) | 1.12 (1.05–1.19) | 1.08 (1.01–1.16) |
ORadjb (95% CI) | 1.03 (0.98–1.08) | 0.97 (0.92–1.02) | 1.05 (0.89–1.25) | 1.14 (1.10–1.19) | 1.13 (1.05–1.21) | 0.98 (0.92–1.05) | 1.04 (0.98–1.10) | 1.00 (0.89–1.13) | 1.01 (0.97–1.07) | 1.10 (1.02–1.18) | 1.06 (0.98–1.14) |